58,332 Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Bought by Toronto Dominion Bank

Toronto Dominion Bank bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 58,332 shares of the company's stock, valued at approximately $1,131,000. Toronto Dominion Bank owned about 0.17% of Oruka Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $144,000. Squarepoint Ops LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $236,000. Finally, Wellington Management Group LLP boosted its stake in shares of Oruka Therapeutics by 15.8% in the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after buying an additional 12,952 shares during the period. Institutional investors and hedge funds own 56.44% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ORKA shares. HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. BTIG Research started coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a "buy" rating for the company. Wolfe Research assumed coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price target for the company. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Oruka Therapeutics has an average rating of "Buy" and an average target price of $40.38.

Oruka Therapeutics Stock Down 2.2%

Shares of NASDAQ:ORKA traded down $0.26 during trading on Wednesday, hitting $11.68. 115,108 shares of the company were exchanged, compared to its average volume of 224,208. The business's 50 day moving average is $9.72 and its 200-day moving average is $13.50. The company has a market capitalization of $437.31 million, a P/E ratio of -1.87 and a beta of 0.25. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.